Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC combined with camrelizumab and lenvatinib for primary liver cancer with portal vein tumor thrombus
ChiCTR2200063129Phase 2Recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of camrelizumab and lenvatinib, sponsored by Shenzhen Third People's Hospital. Started Sep 2022; status: recruiting.
02
Drugs
camrelizumablenvatinib
Beyond the preview
Go deeper on ChiCTR2200063129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063129.